Literature DB >> 12381874

Studies on stibanate unresponsive isolates of Leishmania donovani.

Anindita Bhattacharyya1, Mandira Mukherjee, Swadesh Duttagupta.   

Abstract

Visceral leishmaniasis, also known as kala-azar (KA) is generally caused by Leishmania donovani. Organic pentavalent antimonials (SbV) is the first line of treatment for KA. However, the number of KA patients unresponsive to treatment with Sb(V) is steadily increasing in India and elsewhere. The primary objective of this work is to determine the factor(s) associated with the rise of unresponsiveness. Analysis of the clonal population of parasites clearly indicated that wild type parasites isolated from KA patients who were clinically cured after treatment with Sb(V), were a mixture of resistant and sensitive cells. The resistant promastigotes were also resistant as amastigotes in vivo. It was further observed that Stibanate sensitive parasites can be made resistant to the drug by repeated passages in experimental animals followed by incomplete treatment with suboptimal doses of the drug. These results suggest that the steady rise in Sb(V) unresponsiveness of KA patients in India is due to infection with resistant parasites, generated as a result of irregular and often incomplete treatment of the patients

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381874     DOI: 10.1007/BF02705047

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  9 in total

1.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

2.  Studies on stibanate resistant Leishmania donovani isolates of Indian origin.

Authors:  S Pal; A Mandal; S Duttagupta
Journal:  Indian J Exp Biol       Date:  2001-03       Impact factor: 0.818

3.  Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.

Authors:  C P Thakur; M Kumar; P Kumar; B N Mishra; A K Pandey
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

4.  In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.

Authors:  F Faraut-Gambarelli; R Piarroux; M Deniau; B Giusiano; P Marty; G Michel; B Faugère; H Dumon
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

5.  Leishmania donovani: isolation and characterization of sodium stibogluconate (Pentostam)-resistant cell lines.

Authors:  B Ullman; E Carrero-Valenzuela; T Coons
Journal:  Exp Parasitol       Date:  1989-08       Impact factor: 2.011

6.  Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

Authors:  C P Thakur; G P Sinha; A K Pandey; N Kumar; P Kumar; S M Hassan; S Narain; R K Roy
Journal:  Ann Trop Med Parasitol       Date:  1998-07

7.  Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages.

Authors:  J D Berman; L S Lee
Journal:  J Parasitol       Date:  1984-04       Impact factor: 1.276

8.  The experimental chemotherapy of leishmaniasis, IV. The development of a rodent model for visceral infection.

Authors:  E R Trotter; W Peters; B L Robinson
Journal:  Ann Trop Med Parasitol       Date:  1980-04

9.  Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing.

Authors:  M E Ibrahim; M Hag-Ali; A M el-Hassan; T G Theander; A Kharazmi
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

  9 in total
  4 in total

1.  Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.

Authors:  Anuradha Dube; Nasib Singh; Shyam Sundar; Neeloo Singh
Journal:  Parasitol Res       Date:  2005-05-03       Impact factor: 2.289

2.  Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.

Authors:  Jayeeta Roychoudhury; Roma Sinha; Nahid Ali
Journal:  PLoS One       Date:  2011-03-10       Impact factor: 3.240

3.  Phenotypic diversity and selection maintain Leishmania amazonensis infectivity in BALB/c mouse model.

Authors:  Benoît Espiau; Virginia Vilhena; Armelle Cuvillier; Aldina Barral; Gilles Merlin
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-01-01       Impact factor: 2.743

4.  Comparison of Agar Dilution, Broth Dilution, Cylinder Plate and Disk Diffusion Methods for Evaluation of Anti-leishmanial Drugs on Leishmania promastigotes.

Authors:  T Mohammadzadeh; Sm Sadjjadi; P Habibi; B Sarkari
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.